Breast cancer treatment: a review
AG Waks, EP Winer - Jama, 2019 - jamanetwork.com
Importance Breast cancer will be diagnosed in 12% of women in the United States over the
course of their lifetimes and more than 250 000 new cases of breast cancer were diagnosed …
course of their lifetimes and more than 250 000 new cases of breast cancer were diagnosed …
Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer
Hormone receptor (HR)‐positive and human epidermal growth factor receptor 2 (HER2)‐
negative breast cancer is defined by the presence of the estrogen receptor and/or the …
negative breast cancer is defined by the presence of the estrogen receptor and/or the …
[HTML][HTML] 21-gene assay to inform chemotherapy benefit in node-positive breast cancer
K Kalinsky, WE Barlow, JR Gralow… - … England Journal of …, 2021 - Mass Medical Soc
Background The recurrence score based on the 21-gene breast-cancer assay has been
clinically useful in predicting a chemotherapy benefit in hormone-receptor–positive, human …
clinically useful in predicting a chemotherapy benefit in hormone-receptor–positive, human …
Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer
Background The recurrence score based on the 21-gene breast cancer assay predicts
chemotherapy benefit if it is high and a low risk of recurrence in the absence of …
chemotherapy benefit if it is high and a low risk of recurrence in the absence of …
[HTML][HTML] Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early …
A Goldhirsch, EP Winer, AS Coates, RD Gelber… - Annals of oncology, 2013 - Elsevier
Abstract The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel
reviewed and endorsed substantial new evidence on aspects of the local and regional …
reviewed and endorsed substantial new evidence on aspects of the local and regional …
Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology
WJ Gradishar, MS Moran, J Abraham… - Journal of the National …, 2024 - jnccn.org
Breast cancer is treated with a multidisciplinary approach involving surgical oncology,
radiation oncology, and medical oncology. The NCCN Clinical Practice Guidelines in …
radiation oncology, and medical oncology. The NCCN Clinical Practice Guidelines in …
[HTML][HTML] Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early …
Abstract The 12th St Gallen International Breast Cancer Conference (2011) Expert Panel
adopted a new approach to the classification of patients for therapeutic purposes based on …
adopted a new approach to the classification of patients for therapeutic purposes based on …
Prospective validation of a 21-gene expression assay in breast cancer
Background Prior studies with the use of a prospective–retrospective design including
archival tumor samples have shown that gene-expression assays provide clinically useful …
archival tumor samples have shown that gene-expression assays provide clinically useful …
Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial
AE Giuliano, KK Hunt, KV Ballman, PD Beitsch… - Jama, 2011 - jamanetwork.com
Context Sentinel lymph node dissection (SLND) accurately identifies nodal metastasis of
early breast cancer, but it is not clear whether further nodal dissection affects survival …
early breast cancer, but it is not clear whether further nodal dissection affects survival …
NCCN guidelines® insights: Breast cancer, version 4.2021: Featured updates to the NCCN guidelines
WJ Gradishar, MS Moran, J Abraham, R Aft… - Journal of the National …, 2021 - jnccn.org
The NCCN Guidelines for Breast Cancer include up-to-date guidelines for clinical
management of patients with carcinoma in situ, invasive breast cancer, Paget disease …
management of patients with carcinoma in situ, invasive breast cancer, Paget disease …